


Innovation in Urothelial cancer

Dirigido a profesionales
Formato presencial y online



Inscríbete / sign up
[AQUÍ / HERE](#)

12 November 2026
16:00-18:30 (CET) · Hybrid format

Hospital Universitario HM Sanchinarro,
Auditorio Reina Sofía
C/ de Oña, 10, 28050 Madrid

Organiza:



Director:

Dra. Elena Sevillano Fernández
M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y piel
HM Hospitales

Coordinador

Dr. Jesús García-Donas
M.D PhD M.D. Unidad de Tumores Urológicos, Ginecológicos y piel

Programa

Precision Bladder Cancer: ctDNA, ADCs and the Future of Organ Preservation”
Speakers: *Dr. Joaquim Bellmunt Dr. Pablo Gajate Dra. Elena Sevillano*
Dr. Guillermo de Velasco Dr. Alfonso Gómez de Liaño Dr. Jesús García-Donas
Dr. Félix Guerrero

16:00 – 16:10 | Welcome and Introduction.
From Radical Surgery to Molecular Personalization
- Why urothelial cancer is changing faster than ever
- The transition from standard algorithms to precision

SESSION I – NON–MUSCLE–INVASIVE DISEASE
16:10 – 16:40 | BCG-Unresponsive Disease in 2026: Are We Replacing Cystectomy?
- IO + BCG combinations
- TAR-200, CG0070, N-803 and novel intravesical platforms
- How should we redefine BCG failure?
- Who should still undergo early cystectomy?
- Biomarkers for NMIBC decision-making

SESSION II – SESSION II — MIBC & BLADDER-SPARING
16:40 – 17:25 | The New Era of Bladder Preservation
- ctDNA-guided strategies
- Defining true clinical complete response
- Response-adapted treatment approaches
- Can we safely omit cystectomy?
- Is ctDNA clearance a surrogate endpoint?
- Focused talks, expert debate and real-world cases

SESSION III – ADVANCED UROTHELIAL CANCER
17:25 – 18:00 | After EV-Pembrolizumab: What Comes Next?
- Sequencing ADCs after EV-P
- FGFR3 inhibition in 2026
- HER2-directed therapies
- Mechanisms of resistance
- Platinum-free strategies
- Triplets and novel combinations
- Real-world treatment algorithms

FINAL PANEL & TAKE-HOME MESSAGES
18:00 – 18:30 | What Will Change Clinical Practice in 2027?
- Will ctDNA become standard of care?
- Are ADCs replacing chemotherapy?
- Will bladder preservation become mainstream?
- Which biomarkers are truly ready for clinical implementation?
- Top practice-changing messages of 2026
- Key unanswered questions

FORMAT | Tumor biology · ctDNA and biomarkers ·
Therapeutic personalization · ADCs and precision medicine

TRENDING TOPICS | Clinical debates · Practical cases ·
Dynamic format · Real-world decisions